12-07-2020 --- NCT02859961 Enrollment 556 St
Post# of 155159
(Total Views: 387)
Posted On: 07/15/2025 10:08:38 PM
12-07-2020 --- NCT02859961
Enrollment 556
Study Arms:
350mg 525mg 700mg
Study Completion Date (Actual)
12-07-2020
Under Secondary Outcomes:
Time Frame: 48 weeks
Outcome Measure:
Mean change in CD4 cell count, at each visit within the Treatment Phase
https://clinicaltrials.gov/study/NCT02859961?...;tab=table
___
Of the 12 trials on clinicalTrials .Gov, it is largest enrollment & was the only dose escalation trial.
Is still within the FDA 5 year sample retention rule.
Cytodyn has historical Leronlimab dosing levels on CD4 results, for the CCR5 RO assay to verify again, Leronlimab is upregulating CD4+ T Cells counts
Enrollment 556
Study Arms:
350mg 525mg 700mg
Study Completion Date (Actual)
12-07-2020
Under Secondary Outcomes:
Time Frame: 48 weeks
Outcome Measure:
Mean change in CD4 cell count, at each visit within the Treatment Phase
https://clinicaltrials.gov/study/NCT02859961?...;tab=table
___
Of the 12 trials on clinicalTrials .Gov, it is largest enrollment & was the only dose escalation trial.
Is still within the FDA 5 year sample retention rule.
Cytodyn has historical Leronlimab dosing levels on CD4 results, for the CCR5 RO assay to verify again, Leronlimab is upregulating CD4+ T Cells counts
(5)
(0)